Stocks Declined: USG Corporation, Total System Services, Hercules Offshore, Amicus Therapeutics

Lakeway, TX -- (SBWIRE) -- 02/21/2013 -- Bestdamnpennystocks, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

USG Corporation (NYSE:USG) decreased 6.45% and closed at $28.13 on a traded volume of 2.87 million shares. Barclays started coverage on the stock with overweight rating. USG Corporation is a manufacturer and distributor of building materials. The Company produces a range of products for use in new residential, new nonresidential, and residential and nonresidential repair and remodel construction, as well as products used in certain industrial processes.

How Should Investors Trade USG After The Recent Movement? Find Out Here

Total System Services, Inc. (NYSE:TSS) slipped 6.43% and closed at $21.97 on a traded volume of 7.27 million shares. TSYS have entered into a definitive agreement pursuant to which TSYS will acquire NetSpend in an all cash transaction valued at approximately $1.4 billion. Under terms of the agreement, NetSpend shareholders will receive $16.00 in cash for each share of NetSpend common stock. TSYS expects the transaction to be accretive to GAAP EPS for the first 12 month period following closing.

Is TSS Strong Buy After The Recent Strong Gains? Get Free Trend Analysis Here

Hercules Offshore, Inc. (NASDAQ:HERO) decreased 6.42% and closed at $6.71 on a traded volume of 4.21 million shares. In the last one year, the stock is up over 26%. The 52-week range for the stock is $2.91 and $7.42. Hercules Offshore, Inc. provides shallow-water drilling and marine services to the oil and natural gas exploration and production industry globally. It provides these services to national oil and gas companies, integrated energy companies and independent oil and natural gas operators.

Is HERO a Buying Opportunity After The Recent Plunge? Don’t Miss Out Our Latest Report Here

Amicus Therapeutics, Inc. (NASDAQ:FOLD) moved down 6.40% and closed at $2.78 on a traded volume of 1.65 million shares. The Company announced additional 6-month results from the first ongoing Phase 3 global registration study of investigational oral migalastat HCl monotherapy in males and females with Fabry disease who had genetic mutations identified as amenable to migalastat HCl in a cell-based assay.

How Should Investors Trade FOLD After The Latest Earnings Report? Find Out Here

About bestdamnpennystocks.com
Best Damn Penny Stocks’ team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.

Disclaimer
The assembled information disseminated by Bestdamnpennystocks.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Bestdamnpennystocks.com does expect that investors will buy and sell securities based on information assembled and presented in Bestdamnpennystocks.com. PLEASE always do your own due diligence, and consult your financial advisor.